The Jharkhand government has decided to set up dedicated Rapid Antigen Test booths in villages for mass testing of Covid-19 following an ICMR directive of prioritising rapid tests over RT PCR in the current scenario, officials from the health department said on Thursday.
The dedicated rapid Covid testing centres will also help in identifying positive cases among the several thousand migrant labourers who have started returning to Jharkhand after many states enforced lockdowns in the wake of the surge in Covid cases, health officials said.
Many migrant workers had reportedly dodged mandatory Covid testing at railway stations in the state recently. Such people could be tested in the villages itself once the dedicated RAT centres are set up, officials said.
Covid Vaccines Speed Up Production Of Antibodies In Those Who Have Recovered From Infection: BHU Study
A new study conducted by Banaras Hindu University, has established that the first dose of the Covid-19 vaccine produces antibodies in those who have recovered from the disease within as short a timespan as 10 days PTI Jeevan Prakash Sharma 2021-05-05T11:03:00+05:30 Covid Vaccines Speed Up Production Of Antibodies In Those Who Have Recovered From Infection: BHU Study outlookindia.com 2021-05-05T11:08:51+05:30
Also read
The research highlights the role and benefits of natural antibodies against the SARS-CoV-2 virus responsible for Covid.
The study has established that if a recovered person loses his antibodies after a few months of recovery, his memory cells help produce faster immunity in case of reinfection.
Companies other than Bharat Biotech must be given contracts to manufacture the indigenously developed Covaxin in bulk. This is the time to open licensing to any company that wants to produce vaccines and for anyone who wants to take a jab, per doctors.
The FDA declined to put a timeline to the approval.
The Food and Drug Administration (FDA) is set to approve the use of the Pfizer-BioNTech two-dose mRNA COVID-19 vaccine for children 12-15 years old according to reports in the American press. The rollout could begin as early as next week. More than 131 million shots of the Pfizer vaccine have been used to date in the U.S., and the extension to adolescents could assist with school re-opening later this year.
The Pfizer-BioNTech vaccine one of two mRNA vaccines (the other is from Moderna) that have Emergency Use Authorisation (EUA) fin the U.S. for use in people 16 years and older is likely to be cleared for EUA for adolescents as early as this week, as per reports, which were based on comments from FDA officials. The day after the FDA’s expected approval, the U.S. Centre for Disease Control and Prevention (CDC) will likely meet to give the vaccine the go ahead for use in adolescents, the